Tags:BioTechMedtechProductSupply
AngioLab, Inc. is Korean Biotechnology Company established in June 1999, developing pharmaceutical products based on angiogenesis inhibition to treat and/or prevent various angiogenesis-dependent diseases, such as cancers, ocular diseases, abdominal obesity, psoriasis and arthritis.
AngioLab focuses at this stage on 3 products: abdominal obesity; functional dietary supplement for abdominal obesity; functional cosmeceuticals and Wrinklestat.
Exit: Sale of shares 2018
http://www.angiolab.co.kr
Investors 3
Mentions in press and media 1
